-
Published on Sep 20, 2016
Tom
Piotrowski speaks with Bionomics (BNO) CEO & Managing Director,
Deborah Rathjen about clinical trial results of its anxiety drug BNC210
and its Phase 2 trial for managing Post Traumatic Stress Disorder (PTSD).
http://www.4-traders.com/BIONOMICS-LTD-7136133/
www.bionomics.com.au/
http://www.4-traders.com/BIONOMICS-LTD-7136133/
www.bionomics.com.au/
Media coverage of @Bionomics1 full year financial results: https://t.co/l8VkZfBDqL #biotech pic.twitter.com/W2AmhSPvfS— Bionomics News (@Bionomics1) August 10, 2016
No comments:
Post a Comment